Table 3.

Pathologic findings in patients with COVID-19 who underwent kidney biopsy

PtDiagnosisLight MicroscopyElectron Microscopy
DiagnosisOther FindingsNo. GlomNo. GSNo. CollapseNo. Noncollapsed FSGSHypercellularityMicrocystsIIIFTAVSFPETRIViral Particles
1Collapsing FSGSATI200140NYFocalMildMildNAaNAaN
2Collapsing FSGSATI8320NYFocalModerateModerate to severe100YN
3Collapsing FSGSATI18441NYNoneModerateModerate30NN
4Collapsing FSGSATI10150NNFocalSevereMildNANANA
5Collapsing FSGSATI11370NYFocalSevereModerate to severe90NN
8ATIPigment casts22000NNNoneNoneMild10YN
11MGNPLA2R stain positiveb15304NNFocalMildMild to moderate100NN
12MGNPLA2R stain negativeb3200NYFocalModerateModerate to severe30YN
13LN class 4+535900Mes, Endo, CrescentsNDiffuseMildMild90YN
14Anti-GBM GNATI, RBC casts32100CrescentsYDiffuseMildModerateNAaNAaN
15TCMR grade 2A11100NNFocalNoneMildNANANA
  • Pt, patient; glom, No., number; glomerulus or glomeruli; GS, global sclerosis; II, interstitial inflammation; IFTA, tubular atrophy and interstitial fibrosis; VS, vascular sclerosis; FPE, foot process effacement (percentage); N, no; Y, yes; NA, not available; MCD, minimal change disease; LN, lupus nephritis; Mes, mesangial hypercellularity; Endo, endocapillary hypercellularity; RBC, red blood cell; TCMR, T cell–mediated rejection.

  • a All glomeruli were involved by crescents in the patient with anti-GBM GN, and no glomeruli were available for ultrastructural examination in two patients with native kidney biopsies.

  • b Performed by tissue staining.

  • c Nephrectomy specimen.